DOCSLIB.ORG

Effective for Cases Diagnosed January 1, 2016 and Later

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effective for Cases Diagnosed January 1, 2016 and Later POLICY AND PROCEDURE MANUAL FOR REPORTING FACILITIES May 2016 Effective For Cases Diagnosed January 1, 2016 and Later Indiana State Cancer Registry Indiana State Department of Health 2 North Meridian Street, Section 6-B Indianapolis, IN 46204-3010 TABLE OF CONTENTS INDIANA STATE DEPARTMENT OF HEALTH STAFF ............................................................................. viii INDIANA STATE DEPARTMENT OF HEALTH CANCER REGISTRY STAFF .......................................... ix ACKNOWLEDGMENTS ................................................................................................................................ x INTRODUCTION ........................................................................................................................................... 1 A. Background ..................................................................................................................................... 1 B. Purpose .......................................................................................................................................... 1 C. Definitions ....................................................................................................................................... 1 D. Reference Materials........................................................................................................................ 1 E. Consultation .................................................................................................................................... 2 F. Output ............................................................................................................................................. 2 G. Quality Control ................................................................................................................................ 2 CHAPTER 1: REFERENCES ...................................................................................................................... 3 A. Required References ...................................................................................................................... 3 B. Additional Resources ...................................................................................................................... 3 C. Historic References ........................................................................................................................ 5 CHAPTER 2: CASEFINDING & SETTING UP A REGISTRY ..................................................................... 6 A. Overview ......................................................................................................................................... 6 B. Reportable List ................................................................................................................................ 6 C. Methods Of Casefinding ................................................................................................................. 6 D. Suspense System ........................................................................................................................... 9 E. Accession Register ......................................................................................................................... 9 F. Patient Index ................................................................................................................................. 10 G. Filing ............................................................................................................................................. 11 CHAPTER 3: REPORTING........................................................................................................................ 13 A. Overview ....................................................................................................................................... 13 B. Cases to Report to the State Registry .......................................................................................... 13 C. Cases Not Required ..................................................................................................................... 15 D. Data Items To Report ................................................................................................................... 16 E. Who Should Submit Reports ........................................................................................................ 18 F. When To Submit Reports ............................................................................................................. 18 G. How To Submit Reports ............................................................................................................... 18 CHAPTER 4: GENERAL DEFINITIONS FOR CODING ............................................................................ 21 A. Introduction ................................................................................................................................... 21 B. Guidelines For Interpretation Of Terminology .............................................................................. 21 CHAPTER 5: CODING INSTRUCTIONS .................................................................................................. 27 Overview ............................................................................................................................................... 27 When To Abstract A Cancer Case ....................................................................................................... 27 General Abstracting Instructions And Definitions ................................................................................. 28 State Data Set ...................................................................................................................................... 29 Reporting Facility ID Number ............................................................................................................... 36 NPI-Reporting Facility ........................................................................................................................... 37 Abstracted By ....................................................................................................................................... 38 Type Of Reporting Source .................................................................................................................... 39 Suspense Case .................................................................................................................................... 41 Patient Last Name ................................................................................................................................ 42 Patient First Name ................................................................................................................................ 43 Patient Middle Name (Middle Initial) ..................................................................................................... 44 Patient Maiden Name ........................................................................................................................... 45 Patient Alias .......................................................................................................................................... 46 Indiana Cancer Registry 2016 i Table Of Contents General Guidelines For Recording Patient Address At Diagnosis ....................................................... 47 Patient Address (Number And Street) At Diagnosis ............................................................................. 48 Patient Address (Number And Street) At Diagnosis – Supplemental .................................................. 49 City/Town At Diagnosis ........................................................................................................................ 50 State At Diagnosis ................................................................................................................................ 51 Postal Code (ZIP Code) At Diagnosis .................................................................................................. 53 County At Diagnosis ............................................................................................................................. 54 Census Tract 2000 ............................................................................................................................... 56 Census Tract Certainty 2000 ................................................................................................................ 57 Social Security Number ........................................................................................................................ 58 Date Of Birth ......................................................................................................................................... 59 Date Of Birth Flag ................................................................................................................................. 60 Age At Diagnosis .................................................................................................................................. 61 Place Of Birth ........................................................................................................................................ 62 Birthplace - State .................................................................................................................................. 63 Birthplace - Country .............................................................................................................................
Load more

Recommended publications
  • Table of Contents
    ANTICANCER RESEARCH International Journal of Cancer Research and Treatment ISSN: 0250-7005 Volume 32, Number 4, April 2012 Contents Experimental Studies * Review: Multiple Associations Between a Broad Spectrum of Autoimmune Diseases, Chronic Inflammatory Diseases and Cancer. A.L. FRANKS, J.E. SLANSKY (Aurora, CO, USA)............................................ 1119 Varicella Zoster Virus Infection of Malignant Glioma Cell Cultures: A New Candidate for Oncolytic Virotherapy? H. LESKE, R. HAASE, F. RESTLE, C. SCHICHOR, V. ALBRECHT, M.G. VIZOSO PINTO, J.C. TONN, A. BAIKER, N. THON (Munich; Oberschleissheim, Germany; Zurich, Switzerland) .................................... 1137 Correlation between Adenovirus-neutralizing Antibody Titer and Adenovirus Vector-mediated Transduction Efficiency Following Intratumoral Injection. K. TOMITA, F. SAKURAI, M. TACHIBANA, H. MIZUGUCHI (Osaka, Japan) .......................................................................................................... 1145 Reduction of Tumorigenicity by Placental Extracts. A.M. MARLEAU, G. MCDONALD, J. KOROPATNICK, C.-S. CHEN, D. KOOS (Huntington Beach; Santa Barbara; Loma Linda; San Diego, CA, USA; London, ON, Canada) ...................................................................................................................................... 1153 Stem Cell Markers as Predictors of Oral Cancer Invasion. A. SIU, C. LEE, D. DANG, C. LEE, D.M. RAMOS (San Francisco, CA, USA) ................................................................................................
    [Show full text]
  • Understanding Icd-10-Cm and Icd-10-Pcs 3Rd Edition Download Free
    UNDERSTANDING ICD-10-CM AND ICD-10-PCS 3RD EDITION DOWNLOAD FREE Mary Jo Bowie | 9781305446410 | | | | | International Classification of Diseases, (ICD-10-CM/PCS) Transition - Background Palmer B. Manual placenta removal. A: Understanding ICD-10-CM and ICD-10-PCS 3rd edition International Classification of Diseases ICD is a common framework and language to report, compile, use and compare health information. Psychoanalysis Adlerian therapy Analytical therapy Mentalization-based treatment Transference focused psychotherapy. Hysteroscopy Vacuum aspiration. Every code begins with an alpha character, which is indicative of the chapter to which the code is classified. Search Compliance Understanding BC, resilience standards and how to comply Follow these nine steps to first identify relevant business continuity and resilience standards and, second, launch a successful While many coders use ICD lookup software to help them, referring to an ICD code book is invaluable to build an understanding of the classification system. Pregnancy test Leopold's maneuvers Prenatal testing. Endoscopy : Colonoscopy Anoscopy Capsule endoscopy Enteroscopy Proctoscopy Sigmoidoscopy Abdominal ultrasonography Defecography Double-contrast barium enema Endoanal ultrasound Enteroclysis Lower gastrointestinal series Small-bowel follow-through Transrectal ultrasonography Virtual colonoscopy. Psychosurgery Lobotomy Bilateral cingulotomy Multiple subpial transection Hemispherectomy Corpus callosotomy Anterior temporal lobectomy. While codes in sections are structured similarly to the Medical and Surgical section, there are a few exceptions. Send Feedback Do you have Understanding ICD-10-CM and ICD-10-PCS 3rd edition on the new website? Help Learn to edit Community portal Recent changes Upload file. D Radiation oncology. Stem cell transplantation Hematopoietic stem cell transplantation. The primary distinctions are:. Palmer Joseph C.
    [Show full text]
  • Primary Mixed Myosarcoma of the Uterine Tube: a Case Report and Review of the Literature ALEXANDER S
    Med. J. 258 CASE REPORT: MYOSAIRCOMAMYOSARCOMA OFUTERINEOF UTERINE TUBE Canad.Feb. 3, 1968, Ass.vol. 98 dans 1'cesophage superieur. Le plus petit malade REFERENCES chez qui une biopsie fut prelevee pesait 13 livres 1. CROSBY, W. H.: Amer. or. Dig. Dis., 8: 2, 1963. 2. CAREY, J. B., JR.: Gastroenterology, 46: 550, 1964. et 6tait age de 9 mois. 3. BECK, L T. et al.: Bull. Gastroint. EBndosc., 11: 15, 1965. We wish to thank 0. H. Kimbell, Ph.D., H. Robidoux- 4. MCDONALD, W. G.: Gastroenterology, 51: 390, 1966. 5. PARTIN, J. C. AND SCHUBERT, W. K: New Eng. J. Poirier, R.N., R.-M. Leblanc, R.N., D. Michaud, R.N., Med., 274: 94, 1966. and Marc Gigu6re, R.B.P., for their co-operation and 6. KUITUNEN, P. AND VISAKORPI, J. K.: Lancet, 1: 1276, active assistance. 1965. Primary Mixed Myosarcoma of the Uterine Tube: A Case Report and Review of the Literature ALEXANDER S. ULLMANN, M.D. and MAERIT B. KALLET, M.D., Detroit, Mich., U.S.A. SINCE primary malignant neoplasms of the uterine tube are so rare that no one indi- vidual or clinic has been able to study a large series of patients, the importance of reporting every case has often been emphasized.2-4 Although over 800 cases of primary carcinoma of the tube have been described in the liter- ature,4 up to 1956 only 30 authentic cases of primary sarcoma had been reported and to this number Abrams added another one.1' 8 Recently we had the opportunity to study a patient with primary sarcoma of the fallopian tube.
    [Show full text]
  • Allan Holdsworth Schille Reshaping Harmony
    BJØRN ALLAN HOLDSWORTH SCHILLE RESHAPING HARMONY Master Thesis in Musicology - February 2011 Institute of Musicology| University of Oslo 3001 2 2 Acknowledgment Writing this master thesis has been an incredible rewarding process, and I would like to use this opportunity to express my deepest gratitude to those who have assisted me in my work. Most importantly I would like to thank my wonderful supervisors, Odd Skårberg and Eckhard Baur, for their good advice and guidance. Their continued encouragement and confidence in my work has been a source of strength and motivation throughout these last few years. My thanks to Steve Hunt for his transcription of the chord changes to “Pud Wud” and helpful information regarding his experience of playing with Allan Holdsworth. I also wish to thank Jeremy Poparad for generously providing me with the chord changes to “The Sixteen Men of Tain”. Furthermore I would like to thank Gaute Hellås for his incredible effort of reviewing the text and providing helpful comments where my spelling or formulations was off. His hard work was beyond what any friend could ask for. (I owe you one!) Big thanks to friends and family: Your love, support and patience through the years has always been, and will always be, a source of strength. And finally I wish to acknowledge Arne Torvik for introducing me to the music of Allan Holdsworth so many years ago in a practicing room at the Grieg Academy of Music in Bergen. Looking back, it is obvious that this was one of those life-changing moments; a moment I am sincerely grateful for.
    [Show full text]
  • Uterine Carcinosarcoma Associated with Pelvic Radiotherapy for Sacral Chordoma: a Case Report
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Available online at www.sciencedirect.com Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 89e92 www.tjog-online.com Case Report Uterine carcinosarcoma associated with pelvic radiotherapy for sacral chordoma: A case report Korhan Kahraman a,*, Fırat Ortac a, Duygu Kankaya b, Gulsah Aynaoglu a a Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey b Department of Pathology, Ankara University School of Medicine, Ankara, Turkey Accepted 28 December 2010 Abstract Objective: Postirradiation sarcoma of the female genital tract is rare, but a recognized event. Most reported cases have been associated with history of radiotherapy for various gynecologic conditions, particularly cancer of the uterine cervix and abnormal uterine bleeding. The occurrence of uterine sarcoma secondary to radiotherapy for a non-gynecologic tumor and, furthermore, this condition being simultaneous with the recurrence of primary tumor is unique. Case Report: A 67-year-old woman presented with a uterine mass which was diagnosed as a sarcoma by endometrial curettage and history of pelvic radiotherapy 23 years previously for sacral chordoma. Surgical staging procedure for uterine malignancy was performed. The final pathologic diagnosis was carcinosarcoma of the uterus. Conclusion: In uterine masses seen in patients with history of irradiation to the pelvic field, the probability of uterine sarcomas should always be kept in mind. These tumors may occur simultaneously with recurrence of primary tumor previously treated by adjuvant radiation therapy. Copyright Ó 2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC.
    [Show full text]
  • Hyperthermic Intrathoracic Chemotherapy for Malignant Pleural Mesothelioma: the Forefront of Surgery-Based Multimodality Treatment
    Journal of Clinical Medicine Review Hyperthermic Intrathoracic Chemotherapy for Malignant Pleural Mesothelioma: The Forefront of Surgery-Based Multimodality Treatment Vittorio Aprile 1,†, Alessandra Lenzini 1,†, Filippo Lococo 2, Diana Bacchin 1,* , Stylianos Korasidis 1, Maria Giovanna Mastromarino 1, Giovanni Guglielmi 3, Gerardo Palmiero 4, Marcello Carlo Ambrogi 1 and Marco Lucchi 1 1 Unit of Thoracic Surgery, Department of Critical Area and Surgical, Medical and Molecular Pathology, University of Pisa, 56122 Pisa, Italy; [email protected] (V.A.); [email protected] (A.L.); [email protected] (S.K.); [email protected] (M.G.M.); [email protected] (M.C.A.); [email protected] (M.L.) 2 Thoracic Surgery Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy; fi[email protected] 3 Occupational Health Department, U.O. Medicina Preventiva del Lavoro, Azienda Ospedaliero-Universitaria Pisana, 56122 Pisa, Italy; [email protected] 4 Pneumology Unit, Versilia Hospital, 55049 Camaiore, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0-5099-5230 † These authors contributed equally to this work. Abstract: Introduction: Malignant Pleural Mesothelioma (MPM) is characterized by an aggressive Citation: Aprile, V.; Lenzini, A.; behavior and an inevitably fatal prognosis, whose treatment is still far from being standardized. The Lococo, F.; Bacchin, D.; Korasidis, S.; role of surgery is questionable since a radical resection is unattainable in most cases. Hyperthermic Mastromarino, M.G.; Guglielmi, G.; IntraTHOracic Chemotherapy (HITHOC) combines the advantages of antitumoral effects together Palmiero, G.; Ambrogi, M.C.; Lucchi, with those of high temperature on the exposed tissues with the aim to improve surgical radicality.
    [Show full text]
  • Hodgkin Lymphoma Treatment Regimens
    HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Classical Hodgkin Lymphoma1 Note: All recommendations are Category 2A unless otherwise indicated. Primary Treatment Stage IA, IIA Favorable (No Bulky Disease, <3 Sites of Disease, ESR <50, and No E-lesions) REGIMEN DOSING Doxorubicin + Bleomycin + Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + Vinblastine + Dacarbazine vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over (ABVD) (Category 1)2-5 60 minutes.
    [Show full text]
  • PROPOSED REGULATION of the STATE BOARD of HEALTH LCB File No. R057-16
    PROPOSED REGULATION OF THE STATE BOARD OF HEALTH LCB File No. R057-16 Section 1. Chapter 457 of NAC is hereby amended by adding thereto the following provision: 1. The Division may impose an administrative penalty of $5,000 against any person or organization who is responsible for reporting information on cancer who violates the provisions of NRS 457. 230 and 457.250. 2. The Division shall give notice in the manner set forth in NAC 439.345 before imposing any administrative penalty 3. Any person or organization upon whom the Division imposes an administrative penalty pursuant to this section may appeal the action pursuant to the procedures set forth in NAC 439.300 to 439. 395, inclusive. Section 2. NAC 457.010 is here by amended to read as follows: As used in NAC 457.010 to 457.150, inclusive, unless the context otherwise requires: 1. “Cancer” has the meaning ascribed to it in NRS 457.020. 2. “Division” means the Division of Public and Behavioral Health of the Department of Health and Human Services. 3. “Health care facility” has the meaning ascribed to it in NRS 457.020. 4. “[Malignant neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. [4] “Medical laboratory” has the meaning ascribed to it in NRS 652.060. 5. “Neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. 6. “[Physician] Provider of health care” means a [physician] provider of health care licensed pursuant to chapter [630 or 633] 629.031 of NRS. 7. “Registry” means the office in which the Chief Medical Officer conducts the program for reporting information on cancer and maintains records containing that information.
    [Show full text]
  • Pseudo-Pseudomyxoma Peritonei from Peritoneal Sarcomatosis
    http://crcp.sciedupress.com Case Reports in Clinical Pathology, 2015, Vol. 2, No. 4 CASE REPORT Pseudo-pseudomyxoma peritonei from peritoneal sarcomatosis Shuja Ahmed1, Ling Guo2, Shadi A. Qasem2, Edward A. Levine1 1. Surgical Oncology Service, Department of General Surgery, Wake Forest University School of Medicine, Winston Salem, NC, USA. 2. Department of Pathology, Wake Forest University School of Medicine, Winston Salem, NC, USA. Correspondence: Edward A. Levine, MD. Address: Surgical Oncology Service, Medical Center Blvd, Winston-Salem, North Carolina, USA. E-mail: [email protected] Received: February 12, 2015 Accepted: April 12, 2015 Online Published: June 3, 2015 DOI: 10.5430/crcp.v2n4p14 URL: http://dx.doi.org/10.5430/crcp.v2n4p14 Abstract Background: Pseudomyxoma peritonei (PMP) is a rare clinical entity of mucinous ascites, most commonly associated with appendiceal mucinous neoplasms. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) remains the current standard of care for PMP. Peritoneal sarcomatosis (PS) is an exceptionally rare disease with a poor prognosis. PMP associated with PS has not been previously described. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for PS with or without PMP is not well-defined. PS manifesting like PMP has not been previously described. Case presentation: A 74-year-old patient with several weeks history of vague abdominal pain and increased abdominal girth was referred to our facility after incidental finding of PMP during laparoscopic inguinal hernia repair. After complete work-up, he was advised to undergo CRS/HIPEC. Intra-operatively, he was noted to have extensive mucinous ascites and underwent aggressive CRS and HIPEC Result: Final pathology revealed myxoid liposarcoma with associated intraperitoneal mucin dissemination, which was confirmed with cytogenetic analysis.
    [Show full text]
  • Klatskin Tumors and “Klatskin-Mimicking Lesions”: Our 22- Year Experience
    Title: Klatskin tumors and “Klatskin-mimicking lesions”: our 22- year experience. Authors: Konstantinos Tsalis, Styliani Parpoudi, Dimitrios Kyziridis, Orestis Ioannidis, Natalia Antigoni Savvala, Nikolaos Antoniou, Savvas Symeonidis, Dimitrios Konstantaras, Ioannis Mantzoros, Manousos-Georgios Pramateftakis, Efstathios Kotidis, Stamatios Angelopoulos DOI: 10.17235/reed.2018.5749/2018 Link: PubMed (Epub ahead of print) Please cite this article as: Tsalis Konstantinos, Parpoudi Styliani, Kyziridis Dimitrios, Ioannidis Orestis, Savvala Natalia Antigoni , Antoniou Nikolaos , Symeonidis Savvas, Konstantaras Dimitrios , Mantzoros Ioannis, Pramateftakis Manousos-Georgios, Kotidis Efstathios, Angelopoulos Stamatios. Klatskin tumors and “Klatskin-mimicking lesions”: our 22-year experience. Rev Esp Enferm Dig 2018. doi: 10.17235/reed.2018.5749/2018. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. OR 5749 Klatskin tumors and “Klatskin-mimicking lesions”: our 22-year experience Konstantinos Tsalis, Styliani Parpoudi, Dimitrios Kyziridis, Orestis Ioannidis, Natalia Antigoni-Savvala, Nikolaos Antoniou, Savvas Symeonidis, Dimitrios Konstantaras, Ioannis Mantzoros, Pramateftakis Manousos-George, Kotidis Efstathios and Stamatios Angelopoulos Fourth Surgical Department. Medical School. Aristotle University of Thessaloniki. Thessaloniki, Greece. General Hospital “George Papanikoalou”. Thessaloniki, Greece Received: 04/06/2018 Accepted: 04/09/2018 Correspondence: Orestis Ioannidis. Fourth Surgical Department. Medical School. Aristotle University of Thessaloniki. Thessaloniki, Greece. General Hospital “G.
    [Show full text]
  • Discover Seventh Chords
    Seventh Chords Stack of Thirds - Begin with a major or natural minor scale (use raised leading tone for chords based on ^5 and ^7) - Build a four note stack of thirds on each note within the given key - Identify the characteristic intervals of each of the seventh chords w w w w w w w w % w w w w w w w Mw/M7 mw/m7 m/m7 M/M7 M/m7 m/m7 d/m7 w w w w w w % w w w w #w w #w mw/m7 d/wm7 Mw/M7 m/m7 M/m7 M/M7 d/d7 Seventh Chord Quality - Five common seventh chord types in diatonic music: * Major: Major Triad - Major 7th (M3 - m3 - M3) * Dominant: Major Triad - minor 7th (M3 - m3 - m3) * Minor: minor triad - minor 7th (m3 - M3 - m3) * Half-Diminished: diminished triad - minor 3rd (m3 - m3 - M3) * Diminished: diminished triad - diminished 7th (m3 - m3 - m3) - In the Major Scale (all major scales!) * Major 7th on scale degrees 1 & 4 * Minor 7th on scale degrees 2, 3, 6 * Dominant 7th on scale degree 5 * Half-Diminished 7th on scale degree 7 - In the Minor Scale (all minor scales!) with a raised leading tone for chords on ^5 and ^7 * Major 7th on scale degrees 3 & 6 * Minor 7th on scale degrees 1 & 4 * Dominant 7th on scale degree 5 * Half-Diminished 7th on scale degree 2 * Diminished 7th on scale degree 7 Using Roman Numerals for Triads - Roman Numeral labels allow us to identify any seventh chord within a given key.
    [Show full text]
  • Music in Theory and Practice
    CHAPTER 4 Chords Harmony Primary Triads Roman Numerals TOPICS Chord Triad Position Simple Position Triad Root Position Third Inversion Tertian First Inversion Realization Root Second Inversion Macro Analysis Major Triad Seventh Chords Circle Progression Minor Triad Organum Leading-Tone Progression Diminished Triad Figured Bass Lead Sheet or Fake Sheet Augmented Triad IMPORTANT In the previous chapter, pairs of pitches were assigned specifi c names for identifi cation CONCEPTS purposes. The phenomenon of tones sounding simultaneously frequently includes group- ings of three, four, or more pitches. As with intervals, identifi cation names are assigned to larger tone groupings with specifi c symbols. Harmony is the musical result of tones sounding together. Whereas melody implies the Harmony linear or horizontal aspect of music, harmony refers to the vertical dimension of music. A chord is a harmonic unit with at least three different tones sounding simultaneously. Chord The term includes all possible such sonorities. Figure 4.1 #w w w w w bw & w w w bww w ww w w w w w w w‹ Strictly speaking, a triad is any three-tone chord. However, since western European music Triad of the seventeenth through the nineteenth centuries is tertian (chords containing a super- position of harmonic thirds), the term has come to be limited to a three-note chord built in superposed thirds. The term root refers to the note on which a triad is built. “C major triad” refers to a major Triad Root triad whose root is C. The root is the pitch from which a triad is generated. 73 3711_ben01877_Ch04pp73-94.indd 73 4/10/08 3:58:19 PM Four types of triads are in common use.
    [Show full text]